biotechnology, joined Janssen Pharmaceuticals at Spring House, Pennsylvania, in the Preclinical Sciences and Translational Safety Group as associate scientific director for cellular immunogenicity. He is responsible for supporting immunogenicity risk assessments for Janssen biologics, cell/gene therapy portfolios, as well as overseeing the development, validation and implementation strategies of bioanalytical methodologies for assessing cellular immunogenicity response during nonclinical and clinical development of cell/gene therapies.